Better Buy: Valeant Pharmaceuticals International, Inc. vs. Gilead Sciences
When it comes to the high-flying healthcare sector, there aren't many bargains to be had. President Trump's recent change of heart regarding the possibility of hard caps on high-priced prescription drugs, after all, sparked a widespread rally that's caused valuations to balloon over the past month or so.
Valeant Pharmaceuticals International (NYSE: VRX) and Gilead Sciences (NASDAQ: GILD), however, are two high-profile names that are still arguably "cheap" -- at least based on their rock-bottom price-to-sales ratios of 0.63 and 3.22, respectively. Armed with this insight, let's consider which of these two bargain-bin healthcare stocks is the better buy right now.
Image Source: Getty Images.
Source: Fool.com
Bausch Health Companies Inc. Aktie
6,00 €
-3,05 %
Die Community unterstützt Bausch Health Companies Inc. leicht, mit mehr Buy- als Sell-Einschätzungen.
Das durchschnittliche Community-Kursziel von 16 € für Bausch Health Companies Inc. deutet auf eine Verdopplung des aktuellen Kurses von 6.0 € hin.
